Skip to main content

IDWeek 2024 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

275 Views

A2. PK/PD studies

Poster Session: PK/PD Studies

(P-1251) Pharmacometric Analyses to Support Dose Selection of Zoliflodacin, a First-in-Class Oral Antibiotic Being Developed for the Treatment of Uncomplicated Gonorrhea

Friday, October 18, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

Sujata M. Bhavnani, PharmD; MS; FIDSA

Executive Vice President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States

Co-Author(s)

AC

Anthony P. Cammarata, M.S.

Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
JH

Jeffrey P. Hammel, MS

Director
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
AL

Alison Luckey, MD

Global Antibiotic R&D Partnership (GARDP)
Geneva, Geneve, Switzerland
PD

Pierre Daram, Ph.D.

Global Antibiotic R&D Partnership (GARDP)
Geneva, Geneve, Switzerland
KL

Kajal B. Larson, Ph.D.

Entasis Therapeutics Inc., an affiliate of Innoviva Specialty Therapeutics, Inc.
Waltham, Massachusetts, United States
JO

John P. O'Donnell, B.S.

Entasis Therapeutics Inc., an affiliate of Innoviva Specialty Therapeutics, Inc.
Waltham, Massachusetts, United States
CR

Christopher M. Rubino, PharmD

Executive Vice President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States